Ogilvie’s Syndrome (Acute Colonic Pseudo-Obstruction): Advanced Clinical Review, Imaging Diagnosis, and Management Strategies

on

 

Abstract

Ogilvie’s syndrome, also known as acute colonic pseudo-obstruction (ACPO), is a rare but potentially life-threatening condition characterized by acute colonic dilatation in the absence of mechanical obstruction. This column presents a comprehensive, expert-level review integrating clinical case insights, imaging interpretation, and current global literature. Emphasis is placed on pathophysiology, epidemiology, diagnostic imaging, and evidence-based management strategies, structured in the format of a biomedical review.

Keywords

Ogilvie’s syndrome, acute colonic pseudo-obstruction, colonic dilatation, CT imaging, bowel obstruction, neostigmine, colonoscopic decompression

I. Introduction

Ogilvie’s syndrome is a critical gastrointestinal emergency that mimics mechanical bowel obstruction but lacks any obstructive lesion. First described by Sir William Ogilvie in 1948, this syndrome is increasingly recognized in hospitalized and critically ill patients.

Failure to promptly diagnose and treat ACPO may lead to bowel ischemia, perforation, and mortality rates exceeding 40% in complicated cases. Thus, early radiologic recognition and multidisciplinary management are essential.

II. Case Presentation 

A 68-year-old female with end-stage liver disease secondary to hepatitis C presented with altered mental status due to hepatic encephalopathy. She was treated with lactulose but developed progressive abdominal distension and pain.

Figure 1. Simple Abdomen Radiograph

Diffuse gaseous distension of the colon extending to the splenic flexure. Cecal diameter exceeds 10 cm, suggesting significant colonic dilatation without evidence of mechanical obstruction.

→ Diagnosis: Ogilvie’s syndrome

Figure 2. Abdominal CT (Axial View)

Marked proximal colonic dilatation with an abrupt transition at the descending colon. No obstructing mass or stricture identified, confirming pseudo-obstruction.

III. Pathophysiology

The underlying mechanism of Ogilvie’s syndrome is believed to involve autonomic dysregulation of colonic motility:

  • An imbalance between sympathetic (inhibitory) and parasympathetic (stimulatory) input
  • Reduced parasympathetic activity → decreased peristalsis
  • Functional obstruction → progressive colonic dilation

Key contributing mechanisms:

  • Neurogenic dysfunction (spinal injury, critical illness)
  • Metabolic disturbances (electrolyte imbalance)
  • Pharmacologic suppression (opioids, anticholinergics)

IV. Epidemiology

  • Predominantly affects elderly hospitalized patients
  • Incidence is rising due to increased ICU admissions
  • Common associations:
    • Postoperative states (especially orthopedic surgery)
    • Severe infections
    • Neurological disorders
    • Liver failure (as in this case)

Mortality:

  • Uncomplicated: ~15%
  • Complicated (ischemia/perforation): up to 40–50%

V. Clinical Presentation

Symptoms mimic mechanical bowel obstruction:

  • Abdominal distension (most prominent)
  • Abdominal pain
  • Nausea and vomiting
  • Constipation or paradoxical diarrhea

Important distinguishing features:

  • Absence of peritoneal signs (initially)
  • No leukocytosis or fever in early stages

VI. Imaging Features

1. Plain Radiography

  • Massive colonic dilation
  • Cecum > 9–12 cm → high perforation risk
  • No air-fluid levels are typical of mechanical obstruction

2. CT Imaging (Gold Standard)

  • Diffuse proximal colon dilation
  • Transition zone without an obstructing lesion
  • Evaluation for complications:
    • Ischemia
    • Pneumatosis
    • Perforation

VII. Differential Diagnosis

ConditionKey Distinguishing Feature
Mechanical obstruction    Obstructing mass or stricture
Toxic megacolon    Systemic toxicity + inflammation
Volvulus    Twisting of bowel (coffee bean sign)
Paralytic ileus    Small + large bowel involvement

VIII. Diagnosis

Diagnosis of Ogilvie’s syndrome is based on:

  1. Clinical presentation
  2. Radiologic findings
  3. Exclusion of mechanical obstruction

Key diagnostic criteria:

  • Cecal dilation >10–12 cm
  • No obstructive lesion on CT
  • Compatible clinical context

IX. Treatment

1. Conservative Management (First-line)

  • NPO (bowel rest)
  • IV fluid resuscitation
  • Correction of electrolytes
  • Discontinue causative medications
  • Nasogastric and rectal tube decompression

2. Pharmacologic Therapy

  • Neostigmine (Acetylcholinesterase inhibitor)
    • Stimulates colonic motility
    • Rapid decompression in ~80–90%
    • Contraindications: bradycardia, renal failure

3. Endoscopic Decompression

  • Colonoscopic decompression
  • Effective when neostigmine is contraindicated (as in this case)
  • Risk: perforation (~2%)

4. Surgical Intervention

Indications:

  • Perforation
  • Ischemia
  • Failure of conservative + medical therapy

Procedures:

  • Cecostomy
  • Segmental colectomy

X. Prognosis

  • Good with early treatment
  • Recurrence possible (~20–30%)
  • Poor outcomes associated with:
    • Delayed diagnosis
    • Cecal diameter >12 cm
    • Ischemia or perforation

XI. Quiz Section

Question 1. Which imaging finding is most characteristic of Ogilvie’s syndrome?

A. Small bowel dilation
B. Mechanical obstruction with mass
C. Diffuse colonic dilation without obstruction
D. Air-fluid levels only
E. Free intraperitoneal air

Answer: C. Explanation: ACPO shows massive colonic dilation without mechanical obstruction.

Question 2. What is the first-line pharmacologic treatment?

A. Metoclopramide
B. Neostigmine
C. Atropine
D. Morphine
E. Loperamide

Answer: B. Explanation: Neostigmine increases parasympathetic activity, restoring motility.

Question 3. Which is a contraindication for neostigmine?

A. Hypertension
B. Diabetes
C. Acute renal failure
D. Hyperlipidemia
E. Asthma

Answer: C. Explanation: Neostigmine may worsen bradycardia and is contraindicated in unstable conditions such as renal failure.

XII. Conclusion

Ogilvie’s syndrome is a diagnostic and therapeutic challenge requiring high clinical suspicion. Early imaging recognition, prompt conservative management, and escalation to pharmacologic or procedural interventions are essential to prevent life-threatening complications.

References

[1] W. Ogilvie, “Large-intestine colic due to sympathetic deprivation,” Br Med J, 1948.
[2] J. Vanek and A. Al-Salti, “Acute pseudo-obstruction of the colon (Ogilvie's syndrome),” Dis Colon Rectum, 1986.
[3] M. Saunders, “Systematic review: acute colonic pseudo-obstruction,” Aliment Pharmacol Ther, 2005.
[4] American Society for Gastrointestinal Endoscopy, “Guidelines for ACPO,” Gastrointest Endosc, 2020.
[5] J. Jain et al., “Neostigmine in ACPO,” NEJM, 1999.
[6] J. De Giorgio et al., “Chronic intestinal pseudo-obstruction,” Lancet, 2001.
[7] NEJM Image Challenge, DOI: 10.1056/NEJMicm1311399

Comments

Post a Comment